InsidersTradesSigma
Track the MaxCyte Inc. stock price and the full directors' dealings record of the company, a listed issuer based in United Kingdom. Shares trade on UK GB, under the supervision of RNS (LSE). The latest transaction was reported on 31 January 2024 (Exercise). Among the most active insiders: John Johnston. The full history is openly available.
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
2 of 2 declarations
MaxCyte Inc. is a company specializing in gene and cell transfer technologies. It develops solutions for research and cell therapy.